Stay updated on Merck & Co. Press Releases

Sign up to get notified when there's something new on the Merck & Co. Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Merck & Co. Press Releases page

  1. Check
    7 days ago
    Change Detected
    Summary
    A new news release about Merck's ASCO 2026 data was added to the News releases list. A previously published release announcing the European Commission's RSV approval for ENFLONSIA was removed.
    Difference
    5%
    Check dated 2026-05-18T03:42:52.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Two new news releases were added to the News releases feed: Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate; Merck Completes Acquisition of Terns Pharmaceuticals, Inc. Two older releases were removed from the feed: Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy; Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
    Difference
    6%
    Check dated 2026-05-10T22:18:24.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Two new Merck news releases were added to the News releases feed: April 30, 2026 announcing Merck's first-quarter 2026 financial results with regulatory milestones, and April 28, 2026 about the Playing with Heart program with baseball clubs to raise LDL-C awareness. The feed also removed two older items dated April 2, 2026—the Phase 2b/3 trial initiation for MK-8748 and the European Commission's decision on a KEYTRUDA-based treatment.
    Difference
    6%
    Check dated 2026-05-03T13:40:46.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Updated the “News releases” listing by adding newer dated press releases (from April 20–24, 2026) such as the Hart-Scott-Rodino waiting period expiration for acquiring Terns Pharmaceuticals, a Merck–Google Cloud partnership for agentic AI, FDA approval for IDVYNSO, and additional KEYTRUDA-related updates. Removed earlier dated news releases from late March 2026 (including a Merck-to-hold earnings call item and multiple product/trial/data announcements), shifting the visible results from the prior range (1–10 of 1914) to the latest range (1–10 of 1919).
    Difference
    6%
    Check dated 2026-04-26T08:10:24.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Added two new news releases (April 17, 2026: European Commission approves ENFLONSIA; April 13, 2026: Ifinatamab Deruxtecan granted priority U.S. review). Removed older items (March 16, 2026: ACC.26 Cardio-Pulmonary data; February 28, 2026: KEYTRUDA + WELIREG adjuvant RCC data).
    Difference
    6%
    Check dated 2026-04-19T01:29:42.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    A new news release on April 7, 2026 announces Merck's tender offer to acquire Terns Pharmaceuticals, Inc. The listing for the February 28, 2026 release about WELIREG+LENVIMA has been removed.
    Difference
    5%
    Check dated 2026-04-11T20:59:19.000Z thumbnail image

Stay in the know with updates to Merck & Co. Press Releases

Enter your email address, and we'll notify you when there's something new on the Merck & Co. Press Releases page.